Delivering a Next Generation Platform for Antibody Drug Discovery

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple companies and continues making the AlivaMab Mouse available via non-exclusive licenses.

In June 2018, Deerfield Management and Ablexis signed a definitive agreement under which Deerfield Management will acquire Ablexis.

Year Invested: 2009

Recent News

January 17, 2019
Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company

January 3, 2019
Ablexis Announces Licensing Agreement with Corvidia Therapeutics

December 6, 2018
Ablexis Announces Licensing Agreement with Allogene Therapeutics

Read More News

Associated Team Members

Cary Pfeffer, M.D.